- Barrons.com•1 hour ago
Credit Suisse One of the most common topics of discussion in our investor meetings remains the question around whether Pfizer or another biopharma company may be interested in acquiring Bristol-Myers Squibb in the next nine-12 months, given some of the challenges Bristol-Myers is facing and the activist involvement in the name. To supplement our previous work, our HOLT [proprietary Credit Suisse platform] colleagues have now taken a look at the possibility of Pfizer buying Bristol-Myers from a HOLT perspective and do see the deal as providing an opportunity for value-creation.
- Business Wire•6 hours ago
Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute Announce Collaboration to Accelerate Immuno-Oncology Research
The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company and the Cancer Research Institute today announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology studies across the Parker Institute and CRI networks.
- TheStreet.com•18 hours ago
Sen. Elizabeth Warren and six other lawmakers sent a letter to the billionaire corporate-raider turned activist arguing that he may be breaking federal conflict of interest laws.
BMY : Summary for Bristol-Myers Squibb Company Co - Yahoo Finance
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||55.95 - 56.36|
|52 Week Range||46.01 - 77.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.17|
|Dividend & Yield||1.56 (2.79%)|
|1y Target Est||N/A|